Hu23F2G: Phase I single dose testing is completed, and a multiple-dose regimen will be started this quarter

ICOS Corp. (ICOS), Seattle Product: Hu23F2G Indication: Multiple sclerosis Status: Phase I single dose testing is completed, and a multiple-dose regimen will be started this quarter ...